Diabetes Mellitus, Type 2
Conditions
Brief summary
The aim of this study is to understand, in adult patients with Type 2 diabetes mellitus, if the use of telemedicine (monitoring and treatment without patients having to attend a healthcare facility) and home-based care is more effective than traditional general practitioner (GP) and outpatient care in terms of patients taking medication regularly and their quality of life. The hypothesis of this study is that patients with Type 2 diabetes mellitus uploading data on a telemedicine system achieve a glycemic control, evaluated in terms of glycated hemoglobin levels, similar to that of patients followed in a traditional diabetes outpatient department, with improvements to quality of life
Detailed description
Background and study aims Diabetes mellitus is a long-lasting disease in which the level of blood sugar is higher than normal. High level of sugar in the blood can lead to serious consequences, including blindness, kidney failure, amputation of limbs, coma and death. Patients with diabetes need to regularly take their medicine and to make sure they monitor the level of sugar in their blood on daily basis. This can affect their quality of life. The aim of this study is to understand if telemedicine (monitoring and treatment without patients having to attend a healthcare facility) and home-based care is more effective than traditional GP and outpatient care in terms of patients taking medication regularly and their quality of life. Who can participate? Men and women who live in the study area, have been diagnosed with type 2 diabetes at least 1 year before the start of the study and have been on the same treatment for at least 3 months. What does the study involve? The participants will be recruited by GPs and doctors working in diabetes centres. Participants will be randomly assigned to one of two groups. One group will be treated and followed according as usual. They will test their blood sugar level at home and record it on paper. They will attend a diabetes outpatient clinic for follow-up. The other group will record the level of blood sugar using a digital home-based system that will send data to the diabetes clinic for follow-up. All participants will receive treatment as appropriate from the clinic. At the end of the study (after 18 months), the two groups will be compared to assess which group achieved a better control of their blood sugar level and which experienced a better quality of life, assessed using a questionnaire. The participants will also have their height, weight, waist circumference, blood pressure, cholesterol and blood fats measured at the beginning and end of the study. What are the possible benefits and risks of participating? All patients will receive medication as usual and the control group will continue to attend outpatient clinic, so there are no additional risks associated with participating in the trial. The telemedicine group might benefit from avoiding the inconvenience of having to attend outpatient clinics and from a more rapid response to changes in their blood sugar level from the clinic.
Interventions
BEHAVIORALtelemonitoring of T2DM
Baseline record of: * Weight * Height * BMI * Abdominal circumference * Winsor Index * ECG * Retinography * Blood level of (fasting values): total cholesterol, HDL cholesterol, LDL cholesterol, blood sugar, triglycerides, glycated hemoglobin These parameters will be checked again at 3, 6 and 18 months in the two groups. Telemedicine group (intervention): * Blood sugar (two measurements per week). * Body weight (weekly) * Blood pressure (weekly) Use of devices that allow the automatic upload of data via wi-fi or web is allowed Control group (control): Routine appointments scheduled by their GPs and specialists in outpatient clinics to record blood sugar levels as per standard GP or specialist physician's indications. Blood sugar level is measured in mg/dl in a drop of capillary blood with the use of standard glucose meter
Sponsors
GPI SpA
Centro Studi Internazionali, Italy
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with type 2 diabetes mellitus (T2DM) 2. Diagnosis of DM made at least 1 year before the start of the study 3. Hypoglycemic treatment remained the same in the 3 months preceding the start of the study
Exclusion criteria
1. Diabetes other than T2DM 2. Pregnant women 3. Chronic conditions other than T2DM 4. Unable to give informed consent 5. Dementia or psychiatric conditions that can affect a person's will or ability to participate in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| glycated hemoglobin (GlyH) level | 18 months | Level of glycated hemoglobin (GlyH) at the end of the study (18 months) in patients followed with telemedicine and in the control group when compared to baseline, with normal GlyH defined as \<5.6%. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Body mass index (BMI) | 18 months | BMI calculated from height and weight at baseline and at the end of the study |
| Abdominal circumference | 18 months | Difference in the abdominal circumference measured at baseline and at the end of the study |
| Triglyceride | 18 months | Blood triglyceride level at baseline and at the end of the study |
| LDL-cholesterol | 18 months | Blood LDL-cholesterol level at baseline and at the end of the study |
| Quality of life perception | 18 months | Quality of life as perceived by the patients measured using the SF-36 questionnaire at baseline, 6 months and at the end of the study (18 months) |
| Diastolic BP | 18 months | Diastolic blood pressure at baseline and at the end of the study |
| Compliance | 18 months | Compliance with blood glucose testing (number of actual measurements/expected number of measurements in the whole timeframe of the study), with participants divided into four groups: poor (\<50%), mediocre (50-70%), good (70-90%), optimal (90-100%) |
| Hyperglycemic events | 18 months | Number of hyperglycemic events during the timeframe of the testing, defined as a spot measure of fasting blood sugar \>300 mg/dl |
| Systolic Blood Pressure (BP) | 18 months | Systolic BP at baseline and at the end of the study |
Countries
Italy
Outcome results
None listed